Talk:Fasudil

This is the talk page for discussing improvements to the Fasudil article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Fasudil.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Sygnis Pharma AG has the distribution rights for that class of drugs.
Memory Alzheimer's study by ASU and the Translational Genomics Research Institute published in the journal Behavioral Neuroscience. Dr. Matthew Huentelman, a TGen scientist and the paper's first author.
Fasudil is used in Japan to aid stroke victims by improving blood flow to the brain.

Information from an article on azcentral.com
http://www.azcentral.com/business/articles/2009/02/01/20090201biz-memory0202.html —Preceding unsigned comment added by Qqtpie (talk • contribs) 14:57, 2 February 2009 (UTC)[reply]

Inhibitor of Dkk1

New research may answer why many recent Alzheimer's clinical trials have failed mentions its use as an experimental inhibitor of Dkk1 in mice. - Rod57 (talk) 17:29, 29 September 2018 (UTC)[reply]

Clinical trials

Would be nice to see a summary of the clinical trials supporting the approval in Japan & China. - And have any been done in in USA/EU/Australia ? - Rod57 (talk) 17:29, 29 September 2018 (UTC)[reply]

Talk:Fasudil

Inhibitor of Dkk1

Clinical trials

Navigation menu

Search